Teal Health
Teal Health Raises $22M Series A for At-Home HPV Cervical Cancer Screening
Teal Health announced $22M in Series A financing on September 22, 2026. Teal Health raised a $22 million Series A led by .406 Ventures to expand partnerships and access to its at-home HPV cervical cancer screening.
Round details
The financing includes backing from .406 Ventures, Emerson Collective, Forerunner, Serena Ventures, MPower Partners. The company did not publish a valuation with the announcement.
- Round: Series A
- Capital announced: $22M
- Total funding reported: $45M
How the company plans to use the capital
Teal Health said the new capital will fuel a growing network of payor, health system, employer, provider, and brand partnerships and support continued hiring across clinical, commercial, technology, and operational functions. The company also said it is expanding direct-purchase options for individuals and organizations.
Why this matters for GTM teams
Teal Health said the funding comes ahead of January 2027 federal guidelines that will require most health plans to cover self-collection for cervical cancer screening.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Teal Health Series A announcement.
Company Info
Investors (5)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


